James W Watters

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. ncbi Multiplexed measurements of gene signatures in different analytes using the Nanostring nCounter Assay System
    Vladislav A Malkov
    Rosetta Inpharmatics, LLC, 401 Terry Ave N, Seattle, WA 98109, USA
    BMC Res Notes 2:80. 2009
  2. ncbi EMT is the dominant program in human colon cancer
    Andre Loboda
    Merck, Sharp and Dohme, West Point, PA 19486, USA
    BMC Med Genomics 4:9. 2011
  3. ncbi A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors
    Andrey Loboda
    Department of Molecular Profiling and Research Informatics, Merck Research Laboratories, West Point, Pennsylvania 19486, USA
    BMC Med Genomics 3:26. 2010
  4. ncbi Comparative expression pathway analysis of human and canine mammary tumors
    Paolo Uva
    IRBM P Angeletti, Merck MRL Rome, Pomezia, Italy
    BMC Genomics 10:135. 2009
  5. ncbi De novo discovery of a gamma-secretase inhibitor response signature using a novel in vivo breast tumor model
    James W Watters
    Department of Molecular Profiling, Merck Research Laboratories, North Wales, Pennsylvania 19454, USA
    Cancer Res 69:8949-57. 2009

Collaborators

  • Andrey Loboda
  • Andre Loboda
  • Hongyue Dai
  • Paolo Uva
  • Vladislav A Malkov
  • Deepak Agrawal
  • Pearl S Huang
  • Laura van't Veer
  • Michael V Nebozhyn
  • Timothy J Yeatman
  • Peter Martin Shaw
  • Carolyne A Buser
  • David B Jackson
  • Rob A E M Tollenaar
  • WILLIAM ARTHUR
  • Michael Nebozhyn
  • Bethany Lynch
  • Michael Chastain
  • Brian Roberts
  • Cloud Paweletz
  • Jannik Andersen
  • Rich Klinghoffer
  • Brian Haines
  • Melissa Chenard
  • Igor Feldman
  • Kumiko Nagashima
  • Pearl Huang
  • Theresa Zhang
  • Jason Frazier
  • Gary Geiss
  • Laura Marconato
  • Amit Kulkarni
  • Francesca Abramo
  • Valentina Zappulli
  • Nicola La Monica
  • Fabio Palombo
  • Gennaro Ciliberto
  • Thomas Fare
  • Luigi Aurisicchio
  • Kyle A Serikawa
  • Noel Balantac
  • Giuseppe Mesiti
  • Afshin Mashadi Hossein
  • Valentina Viti
  • Armin Lahm
  • Emanuele De Rinaldis
  • John Castle

Detail Information

Publications5

  1. ncbi Multiplexed measurements of gene signatures in different analytes using the Nanostring nCounter Assay System
    Vladislav A Malkov
    Rosetta Inpharmatics, LLC, 401 Terry Ave N, Seattle, WA 98109, USA
    BMC Res Notes 2:80. 2009
    ..34-0.41 in log2 scale) for FF total RNA samples. CONCLUSION: The nCounter Analysis System generated robust data for multi-gene expression signatures across three different sample preparation conditions...
  2. ncbi EMT is the dominant program in human colon cancer
    Andre Loboda
    Merck, Sharp and Dohme, West Point, PA 19486, USA
    BMC Med Genomics 4:9. 2011
    ..Colon cancer has been classically described by clinicopathologic features that permit the prediction of outcome only after surgical resection and staging...
  3. ncbi A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors
    Andrey Loboda
    Department of Molecular Profiling and Research Informatics, Merck Research Laboratories, West Point, Pennsylvania 19486, USA
    BMC Med Genomics 3:26. 2010
    ..Therefore, optimal methods for measuring Ras pathway activation are critical. The main focus of our work was to develop a gene expression signature that is predictive of RAS pathway dependence...
  4. ncbi Comparative expression pathway analysis of human and canine mammary tumors
    Paolo Uva
    IRBM P Angeletti, Merck MRL Rome, Pomezia, Italy
    BMC Genomics 10:135. 2009
    ....
  5. ncbi De novo discovery of a gamma-secretase inhibitor response signature using a novel in vivo breast tumor model
    James W Watters
    Department of Molecular Profiling, Merck Research Laboratories, North Wales, Pennsylvania 19454, USA
    Cancer Res 69:8949-57. 2009
    ....